Navigation Links
Promising Therapy for Prostate Cancer
Date:6/22/2009

Experimental drug beat back inoperable cancer in two patients, study claims

MONDAY, June 22 (HealthDay News) -- An experimental drug therapy appears to have helped destroy allegedly inoperable prostate cancer in two patients in a clinical trial.

Use of the immunotherapeutic agent MDX-010, or ipilimumab, in combination with standard hormone and radiation treatments helped eliminate the aggressive tumors, which had already spread into the patients' abdominal areas, according to a report from Mayo Clinic researchers that appears in Discovery's Edge, the Mayo Clinic's online research magazine. Both patients are now considered cancer-free.

"The tumors had shrunk dramatically," co-investigator Dr. Michael Blute, a Mayo urologist and surgeon who operated on both patients, said in a Mayo Clinic news release. "I had never seen anything like this before. I had a hard time finding the cancer. At one point, the pathologist [who was working during surgery] asked if we were sending him samples from the same patient."

Ipilimumab is an antibody that appears to greatly magnify the cancer-killing action of androgen ablation, a hormone therapy that helps shrink prostate cancer by eliminating testosterone from the body. Following the additional treatment, the patients showed steady decreases in their prostate-specific antigen (PSA) counts, a test used to detect prostate cancer, and were deemed eligible for surgery. After surgery, one patient underwent additional radiation therapy.

"This is one of the Holy Grails of prostate cancer research," clinical trial leader Dr. Eugene Kwon, a Mayo Clinic urologist, said of the antibody therapy in the same news release.

The team plans more research into how ipilimumab works and how to optimize its use.

More information

The American Cancer Society has more about prostate cancer.



-- Kevin McKeever



SOURCE: Mayo Clinic, news release, June 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
3. Molecule Promising Against Huntingtons Disease
4. Computerized training of working memory is a promising therapeutic strategy in ADHD
5. Baicalin might be a promising therapeutic tool for severe acute pancreatitis
6. Initial Evaluation of New Nucleus Removal Device Provides Promising Results
7. Promising new TB drug given special status by US and European regulators
8. New Drug Promising Against Tough-to-Treat Kidney Cancer
9. Einstein scientists treat cancer as an infectious disease -- with promising results
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Promising Therapy for Prostate Cancer
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & ... nurses in the world with an estimated 5000 perioperative nurses in attendance ...
(Date:2/6/2016)... ... 2016 , ... With the FCPX LUT: Summer pack from Pixel ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. By manipulating each pixel, LUT's can change each color range differently, it gives ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Love is in ... in a variety of colors, assortments and packaging. This staple for Valentine’s Day is ... Kullen location. , For Valentine’s Day, not only are long-stem roses available, but ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... ORLANDO, Fla. , Feb. 8, 2016 ... and marketing high performance apparel for healthcare and other ... Bold Chief Executive Officer. He replaces Dale ... and remains Chairman. Mr. Bold is also joining Vestagen,s ... in a new class of active barrier technologies that ...
(Date:2/8/2016)... Corporation ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS), ... announced that it will release its financial results for the ... close on February 9, 2016.  At this time, the Company ... results.    About Unilife Corporation --> ... Unilife Corporation UNIS / ASX: UNS) ...
(Date:2/8/2016)... Feb. 8, 2016  Astellas Pharma Inc. President and Chief ... of James Robinson as president, Americas Operations, for ... North and South America , effective April ... representing the commercial organization in the United States ... Masao Yoshida , who is retiring in June ...
Breaking Medicine Technology: